Staurus Announces Issuance of U.S. Patent for Immunoglobulins and Variants Directed Against Pathogenic Microbes
JACKSON, Wyo., Aug. 30, 2016 /PRNewswire/ -- Staurus Pharma LLC, today announced that the United States Patent and Trademark Office has granted a key patent covering the composition of novel Fc variant antibodies for the treatment for Staphylococcus aureus (S.aureus) infections. The immunoglobulins of the claimed Fc variants prevent bacterial virulence factors from neutralizing the effector function of anti-S. aureus therapeutic antibodies. Such Fc modifications can be applied to any existing anti-S.aureus therapeutic monoclonal antibody to improve efficacy.
This newly allowed patent covers proprietary Immunoglobulin Fc modifications, which should significantly expand anti-S.aureus therapeutic opportunities beyond traditional antibiotics. Because mAbs do not bind to the same bacterial targets as antibiotics, this new therapeutic approach could be particularly useful in the treatment of antibiotic resistant infections. They may also complement antibiotics in the management of immunocompromised patients. In addition, mAbs have significantly longer half-lives, providing compliance advantages (single dose) and less toxicity to the normal body flora.
"At Staurus, we have dedicated ourselves to understanding why host anti-S.aureus antibodies are not able to effectively protect patients from life threatening complications following S.aureus infections. Circumventing microbial immune evasion through engineering Fc variant antibodies that do not bind to S.aureus Fc Binding Proteins (FcBPs) is central to this novel approach. Having an issued U.S. patent is a critical step in the development of this important antibody-based therapeutic approach," said Nick Lydon, Co-founder of Staurus Pharma LLC. "The issued patent will protect this novel Fc variant antibody technology and allow Staurus to work with a number of collaborators to select the best anti-S.aureus antibody candidates for further development."
U.S. Patent No. 9,416,171 B2, entitled "Immunoglobulins and variants directed against pathogenic microbes," provides commercial rights in the United States through March 2036.
Company Contact: Stephen F. Keane
Co-founder, Staurus Pharma LLC
(858) 232-5928
[email protected]
www.stauruspharma.com
About Staurus Pharma LLC
Staurus Pharma LLC is a biopharmaceutical company pioneering breakthrough science to develop antibody-based biologics to combat Staphylococcus aureus infections. Based on innovative research by Dr. Nick Lydon, Staurus has developed technology to eliminate the Fc binding problem, providing a new pathway to prevent and treat MRSA and other drug resistant infections. Using its proprietary technology, Staurus plans to create partnerships with leading infectious disease companies. To learn more about Staurus Pharma, please visit our web site at: www.stauruspharma.com
Forward-looking statements
This press release contains statements describing Staurus' goals, expectations, intentions or beliefs and is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Although Staurus' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Staurus. As a result, you are cautioned not to rely on these forward-looking statements.
SOURCE Staurus Pharma LLC
Share this article